Generic Drug-Europe Market Status and Trend Report 2013-2023
Report Summary
Generic Drug-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Generic Drug industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Generic Drug 2013-2017, and development forecast 2018-2023
Main market players of Generic Drug in Europe, with company and product introduction, position in the Generic Drug market
Market status and development trend of Generic Drug by types and applications
Cost and profit status of Generic Drug, and marketing status
Market growth drivers and challenges
The report segments the Europe Generic Drug market as:
Europe Generic Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Generic Drug Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Pure (Non-branded) Generics
Branded Generics
Super Generics
Europe Generic Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Cardiovascular & Hypertension
Dermatology
Diabetes
Rheumatology
Oncology
Gastrointestinal
Others
Europe Generic Drug Market: Players Segment Analysis (Company and Product introduction, Generic Drug Sales Volume, Revenue, Price and Gross Margin):
Teva Pharma.
Novartis company
Mylan
Allergan
Hospira
Dr. Reddy?s Lab.
Stada
Greenstone
Par Pharma
Sun Pharmaceutical
Aspen Pharmacare
Fresenius
Lupin
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Generic Drug-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Generic Drug industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Generic Drug 2013-2017, and development forecast 2018-2023
Main market players of Generic Drug in Europe, with company and product introduction, position in the Generic Drug market
Market status and development trend of Generic Drug by types and applications
Cost and profit status of Generic Drug, and marketing status
Market growth drivers and challenges
The report segments the Europe Generic Drug market as:
Europe Generic Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Generic Drug Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Pure (Non-branded) Generics
Branded Generics
Super Generics
Europe Generic Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Cardiovascular & Hypertension
Dermatology
Diabetes
Rheumatology
Oncology
Gastrointestinal
Others
Europe Generic Drug Market: Players Segment Analysis (Company and Product introduction, Generic Drug Sales Volume, Revenue, Price and Gross Margin):
Teva Pharma.
Novartis company
Mylan
Allergan
Hospira
Dr. Reddy?s Lab.
Stada
Greenstone
Par Pharma
Sun Pharmaceutical
Aspen Pharmacare
Fresenius
Lupin
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF GENERIC DRUG
1.1 Definition of Generic Drug in This Report
1.2 Commercial Types of Generic Drug
1.2.1 Pure (Non-branded) Generics
1.2.2 Branded Generics
1.2.3 Super Generics
1.3 Downstream Application of Generic Drug
1.3.1 Cardiovascular & Hypertension
1.3.2 Dermatology
1.3.3 Diabetes
1.3.4 Rheumatology
1.3.5 Oncology
1.3.6 Gastrointestinal
1.3.7 Others
1.4 Development History of Generic Drug
1.5 Market Status and Trend of Generic Drug 2013-2023
1.5.1 Europe Generic Drug Market Status and Trend 2013-2023
1.5.2 Regional Generic Drug Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Generic Drug in Europe 2013-2017
2.2 Consumption Market of Generic Drug in Europe by Regions
2.2.1 Consumption Volume of Generic Drug in Europe by Regions
2.2.2 Revenue of Generic Drug in Europe by Regions
2.3 Market Analysis of Generic Drug in Europe by Regions
2.3.1 Market Analysis of Generic Drug in Germany 2013-2017
2.3.2 Market Analysis of Generic Drug in United Kingdom 2013-2017
2.3.3 Market Analysis of Generic Drug in France 2013-2017
2.3.4 Market Analysis of Generic Drug in Italy 2013-2017
2.3.5 Market Analysis of Generic Drug in Spain 2013-2017
2.3.6 Market Analysis of Generic Drug in Benelux 2013-2017
2.3.7 Market Analysis of Generic Drug in Russia 2013-2017
2.4 Market Development Forecast of Generic Drug in Europe 2018-2023
2.4.1 Market Development Forecast of Generic Drug in Europe 2018-2023
2.4.2 Market Development Forecast of Generic Drug by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Generic Drug in Europe by Types
3.1.2 Revenue of Generic Drug in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Generic Drug in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Generic Drug in Europe by Downstream Industry
4.2 Demand Volume of Generic Drug by Downstream Industry in Major Countries
4.2.1 Demand Volume of Generic Drug by Downstream Industry in Germany
4.2.2 Demand Volume of Generic Drug by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Generic Drug by Downstream Industry in France
4.2.4 Demand Volume of Generic Drug by Downstream Industry in Italy
4.2.5 Demand Volume of Generic Drug by Downstream Industry in Spain
4.2.6 Demand Volume of Generic Drug by Downstream Industry in Benelux
4.2.7 Demand Volume of Generic Drug by Downstream Industry in Russia
4.3 Market Forecast of Generic Drug in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF GENERIC DRUG
5.1 Europe Economy Situation and Trend Overview
5.2 Generic Drug Downstream Industry Situation and Trend Overview
CHAPTER 6 GENERIC DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Generic Drug in Europe by Major Players
6.2 Revenue of Generic Drug in Europe by Major Players
6.3 Basic Information of Generic Drug by Major Players
6.3.1 Headquarters Location and Established Time of Generic Drug Major Players
6.3.2 Employees and Revenue Level of Generic Drug Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 GENERIC DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Teva Pharma.
7.1.1 Company profile
7.1.2 Representative Generic Drug Product
7.1.3 Generic Drug Sales, Revenue, Price and Gross Margin of Teva Pharma.
7.2 Novartis company
7.2.1 Company profile
7.2.2 Representative Generic Drug Product
7.2.3 Generic Drug Sales, Revenue, Price and Gross Margin of Novartis company
7.3 Mylan
7.3.1 Company profile
7.3.2 Representative Generic Drug Product
7.3.3 Generic Drug Sales, Revenue, Price and Gross Margin of Mylan
7.4 Allergan
7.4.1 Company profile
7.4.2 Representative Generic Drug Product
7.4.3 Generic Drug Sales, Revenue, Price and Gross Margin of Allergan
7.5 Hospira
7.5.1 Company profile
7.5.2 Representative Generic Drug Product
7.5.3 Generic Drug Sales, Revenue, Price and Gross Margin of Hospira
7.6 Dr. Reddy?s Lab.
7.6.1 Company profile
7.6.2 Representative Generic Drug Product
7.6.3 Generic Drug Sales, Revenue, Price and Gross Margin of Dr. Reddy?s Lab.
7.7 Stada
7.7.1 Company profile
7.7.2 Representative Generic Drug Product
7.7.3 Generic Drug Sales, Revenue, Price and Gross Margin of Stada
7.8 Greenstone
7.8.1 Company profile
7.8.2 Representative Generic Drug Product
7.8.3 Generic Drug Sales, Revenue, Price and Gross Margin of Greenstone
7.9 Par Pharma
7.9.1 Company profile
7.9.2 Representative Generic Drug Product
7.9.3 Generic Drug Sales, Revenue, Price and Gross Margin of Par Pharma
7.10 Sun Pharmaceutical
7.10.1 Company profile
7.10.2 Representative Generic Drug Product
7.10.3 Generic Drug Sales, Revenue, Price and Gross Margin of Sun Pharmaceutical
7.11 Aspen Pharmacare
7.11.1 Company profile
7.11.2 Representative Generic Drug Product
7.11.3 Generic Drug Sales, Revenue, Price and Gross Margin of Aspen Pharmacare
7.12 Fresenius
7.12.1 Company profile
7.12.2 Representative Generic Drug Product
7.12.3 Generic Drug Sales, Revenue, Price and Gross Margin of Fresenius
7.13 Lupin
7.13.1 Company profile
7.13.2 Representative Generic Drug Product
7.13.3 Generic Drug Sales, Revenue, Price and Gross Margin of Lupin
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF GENERIC DRUG
8.1 Industry Chain of Generic Drug
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF GENERIC DRUG
9.1 Cost Structure Analysis of Generic Drug
9.2 Raw Materials Cost Analysis of Generic Drug
9.3 Labor Cost Analysis of Generic Drug
9.4 Manufacturing Expenses Analysis of Generic Drug
CHAPTER 10 MARKETING STATUS ANALYSIS OF GENERIC DRUG
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Generic Drug in This Report
1.2 Commercial Types of Generic Drug
1.2.1 Pure (Non-branded) Generics
1.2.2 Branded Generics
1.2.3 Super Generics
1.3 Downstream Application of Generic Drug
1.3.1 Cardiovascular & Hypertension
1.3.2 Dermatology
1.3.3 Diabetes
1.3.4 Rheumatology
1.3.5 Oncology
1.3.6 Gastrointestinal
1.3.7 Others
1.4 Development History of Generic Drug
1.5 Market Status and Trend of Generic Drug 2013-2023
1.5.1 Europe Generic Drug Market Status and Trend 2013-2023
1.5.2 Regional Generic Drug Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Generic Drug in Europe 2013-2017
2.2 Consumption Market of Generic Drug in Europe by Regions
2.2.1 Consumption Volume of Generic Drug in Europe by Regions
2.2.2 Revenue of Generic Drug in Europe by Regions
2.3 Market Analysis of Generic Drug in Europe by Regions
2.3.1 Market Analysis of Generic Drug in Germany 2013-2017
2.3.2 Market Analysis of Generic Drug in United Kingdom 2013-2017
2.3.3 Market Analysis of Generic Drug in France 2013-2017
2.3.4 Market Analysis of Generic Drug in Italy 2013-2017
2.3.5 Market Analysis of Generic Drug in Spain 2013-2017
2.3.6 Market Analysis of Generic Drug in Benelux 2013-2017
2.3.7 Market Analysis of Generic Drug in Russia 2013-2017
2.4 Market Development Forecast of Generic Drug in Europe 2018-2023
2.4.1 Market Development Forecast of Generic Drug in Europe 2018-2023
2.4.2 Market Development Forecast of Generic Drug by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Generic Drug in Europe by Types
3.1.2 Revenue of Generic Drug in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Generic Drug in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Generic Drug in Europe by Downstream Industry
4.2 Demand Volume of Generic Drug by Downstream Industry in Major Countries
4.2.1 Demand Volume of Generic Drug by Downstream Industry in Germany
4.2.2 Demand Volume of Generic Drug by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Generic Drug by Downstream Industry in France
4.2.4 Demand Volume of Generic Drug by Downstream Industry in Italy
4.2.5 Demand Volume of Generic Drug by Downstream Industry in Spain
4.2.6 Demand Volume of Generic Drug by Downstream Industry in Benelux
4.2.7 Demand Volume of Generic Drug by Downstream Industry in Russia
4.3 Market Forecast of Generic Drug in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF GENERIC DRUG
5.1 Europe Economy Situation and Trend Overview
5.2 Generic Drug Downstream Industry Situation and Trend Overview
CHAPTER 6 GENERIC DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Generic Drug in Europe by Major Players
6.2 Revenue of Generic Drug in Europe by Major Players
6.3 Basic Information of Generic Drug by Major Players
6.3.1 Headquarters Location and Established Time of Generic Drug Major Players
6.3.2 Employees and Revenue Level of Generic Drug Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 GENERIC DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Teva Pharma.
7.1.1 Company profile
7.1.2 Representative Generic Drug Product
7.1.3 Generic Drug Sales, Revenue, Price and Gross Margin of Teva Pharma.
7.2 Novartis company
7.2.1 Company profile
7.2.2 Representative Generic Drug Product
7.2.3 Generic Drug Sales, Revenue, Price and Gross Margin of Novartis company
7.3 Mylan
7.3.1 Company profile
7.3.2 Representative Generic Drug Product
7.3.3 Generic Drug Sales, Revenue, Price and Gross Margin of Mylan
7.4 Allergan
7.4.1 Company profile
7.4.2 Representative Generic Drug Product
7.4.3 Generic Drug Sales, Revenue, Price and Gross Margin of Allergan
7.5 Hospira
7.5.1 Company profile
7.5.2 Representative Generic Drug Product
7.5.3 Generic Drug Sales, Revenue, Price and Gross Margin of Hospira
7.6 Dr. Reddy?s Lab.
7.6.1 Company profile
7.6.2 Representative Generic Drug Product
7.6.3 Generic Drug Sales, Revenue, Price and Gross Margin of Dr. Reddy?s Lab.
7.7 Stada
7.7.1 Company profile
7.7.2 Representative Generic Drug Product
7.7.3 Generic Drug Sales, Revenue, Price and Gross Margin of Stada
7.8 Greenstone
7.8.1 Company profile
7.8.2 Representative Generic Drug Product
7.8.3 Generic Drug Sales, Revenue, Price and Gross Margin of Greenstone
7.9 Par Pharma
7.9.1 Company profile
7.9.2 Representative Generic Drug Product
7.9.3 Generic Drug Sales, Revenue, Price and Gross Margin of Par Pharma
7.10 Sun Pharmaceutical
7.10.1 Company profile
7.10.2 Representative Generic Drug Product
7.10.3 Generic Drug Sales, Revenue, Price and Gross Margin of Sun Pharmaceutical
7.11 Aspen Pharmacare
7.11.1 Company profile
7.11.2 Representative Generic Drug Product
7.11.3 Generic Drug Sales, Revenue, Price and Gross Margin of Aspen Pharmacare
7.12 Fresenius
7.12.1 Company profile
7.12.2 Representative Generic Drug Product
7.12.3 Generic Drug Sales, Revenue, Price and Gross Margin of Fresenius
7.13 Lupin
7.13.1 Company profile
7.13.2 Representative Generic Drug Product
7.13.3 Generic Drug Sales, Revenue, Price and Gross Margin of Lupin
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF GENERIC DRUG
8.1 Industry Chain of Generic Drug
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF GENERIC DRUG
9.1 Cost Structure Analysis of Generic Drug
9.2 Raw Materials Cost Analysis of Generic Drug
9.3 Labor Cost Analysis of Generic Drug
9.4 Manufacturing Expenses Analysis of Generic Drug
CHAPTER 10 MARKETING STATUS ANALYSIS OF GENERIC DRUG
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
